Abstract
Bevacizumab has significantly improved the resectability, response rate and survival of patients with RAS-mutant colorectal cancer liver metastases (CRLM). However, more than half of these patients were insensitive to bevacizumab therapy. Identification of patients who are sensitive to bevacizumab therapy may improve the response rate and reduce adverse events. In this study, we aimed to construct and validate a PET/CT deep radiomics signature to predict bevacizumab efficacy in initially unresectable RAS-mutant CRLM patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have